Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo extends life for aggressive lung cancer patients

NCT ID NCT05683977

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 254 adults with extensive-stage small cell lung cancer who are receiving durvalumab (Imfinzi) along with standard chemotherapy. The goal is to see how long patients stay on treatment and how well it works in real-world settings. The approach uses the immune system to help fight the cancer, but ongoing treatment is needed to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

254 people

The number who actually took part.

Started

Nov 2022

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

* Total population: all patients enrolled * Safety analysis set: the safety population will be defined as all patients who receive at least one infusion of durvalumab. * Full analysis set: the full analysis set will comprise all patients who receive at least one infusion of durvalumab and meet eligibility criteria. * Follow up analysis set: it will comprise all patients of the full analysis set who have at least one follow up visit completed.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients (at least 18 years of age at time of treatment decision), * Patients with histologically or cytologically proven SCLC and extensive disease according to the Veterans Administration Lung Study Group (VALSG) classification or TNM staging (Brierley et al, 2017) before durvalumab + platinum-etoposide treatment\*, * Patients newly treated in first line with durvalumab + platinum-etoposide\*\*, * Patients informed and not opposed to participating in the study. Exclusion Criteria: * Patients with contraindications to receiving durvalumab + platinum-etoposide, * Patients participating in another interventional clinical trial for first line ES-SCLC.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Small cell lung carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Small cell lung carcinoma

Contacts and locations

Locations

  • Research Site

    Angers, 49933, France

  • Research Site

    Argenteuil, 95107, France

  • Research Site

    Avignon, 84000, France

  • Research Site

    Avignon, 84918, France

  • Research Site

    Bayonne, 64100, France

  • Research Site

    Bordeaux, 33077, France

  • Research Site

    Clermont-Ferrand, 63000, France

  • Research Site

    Créteil, 94000, France

  • Research Site

    Dijon, 21000, France

  • Research Site

    Epagny Metz-Tessy, 74370, France

  • Research Site

    Évreux, 27015, France

  • Research Site

    Gleizé, 69400, France

  • Research Site

    La Roche-sur-Yon, 85925, France

  • Research Site

    La Rochelle, 17000, France

  • Research Site

    Le Chesnay-Rocquencourt, 78150, France

  • Research Site

    Limoges, 87000, France

  • Research Site

    Marseille, 13008, France

  • Research Site

    Nancy, 54100, France

  • Research Site

    Nîmes, 30000, France

  • Research Site

    Nîmes, 30900, France

  • Research Site

    Osny, 95520, France

  • Research Site

    Paris, 75005, France

  • Research Site

    Pau, 64000, France

  • Research Site

    Rennes, France

  • Research Site

    Rouen, 76000, France

  • Research Site

    Saint-Etienne, 42100, France

  • Research Site

    Saint-Grégoire, 35760, France

  • Research Site

    Saint-Quentin, 2321, France

  • Research Site

    Toulon, 83000, France

  • Research Site

    Toulouse, 31076, France

  • Research Site

    Toulouse, 31400, France

  • Research Site

    Valenciennes, 59300, France

  • Research Site

    Vannes, 56017, France

  • Research Site

    Villeurbanne, 69100, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.